Advertisement

Topics

Scarab Genomics, LLC Company Profile

10:32 EST 14th December 2018 | BioPortfolio

Scarab Genomics, a Madison, Wisconsin based biotechnology company, was established in 2002 to commercialize the Clean Genome® Multiple Deletion Series (MDS) E. coli that resulted from Dr. Fred Blattner’s first sequencing of E. coli at the University of Wisconsin. Scarab Genomics licensed the patented reduced genome technology from the Wisconsin Alumni Research Foundation on an exclusive, worldwide basis. Genome reduction provides cost reduction as well as enhanced genetic stability and improved product safety, while retaining robust growth on minimal media, making these strains ideal for the production of biotherapeutics. Scarab is now developing and testing additional reduced strains with over 20% of the genes removed for general cloning, plasmid propagation, production of plasmid-based RNAi, DNA vaccines, and recombinant protein-based therapeutics.


News Articles [414 Associated News Articles listed on BioPortfolio]

10X Genomics Prepares to Hire 200 New Employees, Move into Larger Facility

Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.

Microsoft Genomics Ventures into the Microbiome With Eagle Genomics

LONDON, October 15, 2018 /PRNewswire/ -- Cambridge technology innovators partner with Microsoft Genomics Microbiomic research into immune disorders and antibiotic resistance First microbiome partn...

Festival of Genomics London 2018: the landmark event making genomics mainstream

London, UK, 5th January 2018 / Sciad Newswire / This January sees the third edition of Festival of Genomics London, the largest meeting of its kind in the UK. Following two US editions of the event ...

QUANTUM GENOMICS: Quantum Genomics receives ethics committee approval to initiate clinical study of extended-release firibastat tablets

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat hypertension and h...

QUANTUM GENOMICS: Quantum Genomics to Host Key Opinion Leader and Investor Event on December 10, 2018

Event Focused on Phase IIb Arterial Hypertension Data opening the way to a pivotal Phase 3 Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in th...

#jobs #lifescience CK Group: Genomics Manufacturing Technician – Hertfordshire

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CK Group: Genomics Manufacturing Technician – Hertfordshire . £18,000:...

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit

Invests in Genomics England alliance, plus clinical trials expansion

Vertex and Genomics Collaborate to use Human Genetics and Data Science to Advance Discovery of Precision Medicines

NewsMulti-year collaboration combines expertise in genomics, machine learning, and drug discovery to identify novel targets for innovative medicines.

Drugs and Medications [0 Results]

None

PubMed Articles [210 Associated PubMed Articles listed on BioPortfolio]

Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.

Single-cell genomics.

Current Social Media Conversations about Genetics and Genomics in Health: A Twitter-Based Analysis.

The growing availability of genomic information to the public may spur discussion about genetics and genomics on social media. Sites, including Twitter, provide a unique space for the public to access...

Lifestyle Genomics: Addressing the Multifactorial Nature of Personalized Health.

The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results.

Guidelines recommend patients be informed of their incidental results (IR) when undergoing genomic sequencing (GS), yet there are limited tools to support patients' decisions about learning IR. The ai...

Clinical Trials [95 Associated Clinical Trials listed on BioPortfolio]

Evolution of Cardiovascular Function and Quality of Life in Patients Included in the SCArabée Therapeutic Education Program

Coronary artery disease is defined as a disease of the arteries that vascularize the heart, resulting in myocardial ischemia, i.e. insufficient blood supply to the heart muscle. Eventually...

Electronic Medical Records and Genomics (eMERGE) Phase III

The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clini...

Genomics and Postoperative Atrial Fibrillation

This research study is done to find out if genetic make up of a person plays a role in complications and recovery after the Coronary Artery Bypass Graft (CABG) operation. As you may be aw...

Microfluidics and Transcriptomics in Post Solid Organ Transplant Patients

The field of genomics is an exciting new field being applied in medicine. Its use in treating some cancers, sepsis and burn patients has been very promising. As knowledge of genomics and a...

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or p...

Companies [415 Associated Companies listed on BioPortfolio]

Scarab Genomics, LLC

Scarab Genomics, a Madison, Wisconsin based biotechnology company, was established in 2002 to commercialize the Clean Genome® Multiple Deletion Series (MDS) E. coli that result...

Genomics in Business

In 2003 Keygene initiated the first edition of Genomics in Business. It was the first conference to focus on the existing and future applications of genomics in the Agro-Food industry. With participan...

Genomics One Corporation

Genomics One is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and mono-clonal antibodies. The mission...

Center for Genomics and Bioinformatics

Center for Genomics and Bioinformatics The Center for Genomics and Bioinformatics (CGB) was launched in 1997 as a new academic department at the Karolinska Institute. Since then, the department has be...

Front Line Genomics

At Front Line Genomics our mission is to help deliver the benefits of genomics faster. Through our website, our magazine and the Festivals of Genomics, we support scientists, clin...

More Information about "Scarab Genomics, LLC" on BioPortfolio

We have published hundreds of Scarab Genomics, LLC news stories on BioPortfolio along with dozens of Scarab Genomics, LLC Clinical Trials and PubMed Articles about Scarab Genomics, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Scarab Genomics, LLC Companies in our database. You can also find out about relevant Scarab Genomics, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record